Raymond James Financial
HRTX icon

Raymond James Financial’s Heron Therapeutics HRTX Stock Holding History

Raymond James Financial’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$67.5K Buy
158,177
+19,974
+14% +$16K ﹤0.01% 5219
2026
Q1 		$111K Buy
138,203
+18,004
+15% +$20.9K ﹤0.01% 5012
2025
Q4 		$156K Buy
120,199
+8,527
+8% +$10.5K ﹤0.01% 4846
2025
Q3 		$141K Buy
111,672
+450
+0.4% +$713 ﹤0.01% 4691
2025
Q2 		$230K Sell
111,222
-25,000
-18% -$51.1K ﹤0.01% 4443
2025
Q1 		$300K Buy
136,222
+500
+0.4% +$970 ﹤0.01% 4220
2024
Q4 		$208K Buy
+135,722
New +$220K ﹤0.01% 4389

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Raymond James Financial's HRTX Position: Q2 2026 in Review

Raymond James Financial increased its Heron Therapeutics (HRTX) stake by 14% in Q2 2026, buying an estimated $16K and bringing the position to 158,177 shares worth $67.5K. The position accounts for ﹤0.01% of the portfolio, ranked #5219.

Raymond James Financial first reported a position in HRTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $300K in Q1 2025. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Raymond James Financial held 158,177 shares of Heron Therapeutics worth $67.5K as of Q2 2026.
  • Raymond James Financial bought 19,974 Heron Therapeutics shares in Q2 2026, an estimated $16K.
  • Heron Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #5219 holding.
  • Raymond James Financial first reported a position in Heron Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Raymond James Financial's Heron Therapeutics position peaked at $300K in Q1 2025.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.